BioSpace News Archive

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 pivotal cardiovascular outcomes trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), has been accepted for presentation in a virtual Late Breaking Clinical Trial session at t

Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to cloggin

GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace, announced that the company will participate in the Morgan Stanley Global Healthcare Conference on September 18 at 8:00 a.m. (ET).

Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced today the launch of a redesigned website for healthcare professionals (HCPs). This newly redesigned

- Clinical and preclinical data published in Critical Care Explorations demonstrate that EP-7041 has the ability to inhibit ECMO-related thrombosis while minimizing the risk of unwanted bleeding

Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Japan are using the Radixact® System with the Synchrony® Automatic, Real-time Motion Synchronization Technology1 to provide advanced cancer treatments to more patients throughout the country.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (N

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to Zymeworks’ Azymetric™ and EFECT™ platforms for the

Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, today announced the results of a Phase 1 study for a component of the company’s lead combination drug candidate, AD109, which i

Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, cardiovascular and metabolic disorders, viral illnesses—including COVID-19—and inflammatory disorders. The lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) is being developed for both treatment of